These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2417362

  • 21. In vitro adrenaline and collagen-induced mobilization of platelet calcium and its inhibition by naftopidil, doxazosin and nifedipine.
    Alarayyed NA, Cooper MB, Prichard BN, Betteridge DJ, Smith CC.
    Br J Clin Pharmacol; 1997 Apr; 43(4):415-20. PubMed ID: 9146854
    [Abstract] [Full Text] [Related]

  • 22. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil.
    Rostagno C, Abbate R, Gensini GF, Coppo M, Prisco D, Boddi M, Neri Serneri GG.
    Thromb Res; 1991 Aug 15; 63(4):457-62. PubMed ID: 1754998
    [No Abstract] [Full Text] [Related]

  • 23. Anti-aggregatory actions of calcium channel blockers in cat platelets.
    Schmunk GA, Lefer AM.
    Res Commun Chem Pathol Pharmacol; 1982 Feb 15; 35(2):179-87. PubMed ID: 6803310
    [Abstract] [Full Text] [Related]

  • 24. Second messengers in platelet aggregation evoked by serotonin and A23187, a calcium ionophore.
    Connor JD, Rasheed H, Gilani AH, Cheema M, Rizvi Z, Saeed SA.
    Life Sci; 2001 Oct 26; 69(23):2759-64. PubMed ID: 11720080
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effects of calcium channel blockers on in vitro platelet function in whole blood using single platelet counting.
    Walley TJ, Woods KL, Barnett DB.
    Thromb Haemost; 1989 Feb 28; 61(1):137-9. PubMed ID: 2749586
    [Abstract] [Full Text] [Related]

  • 27. Effect of Ca2+-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, on platelet aggregation in vitro.
    Ono H, Kimura M.
    Arzneimittelforschung; 1981 Feb 28; 31(7):1131-4. PubMed ID: 7196762
    [Abstract] [Full Text] [Related]

  • 28. Mepacrine-induced elevation of cyclic GMP levels and acceleration of reversal of ADP-induced aggregation in washed rabbit platelets.
    Matsuoka I, Suzuki T.
    J Cyclic Nucleotide Protein Phosphor Res; 1983 Feb 28; 9(4-5):341-53. PubMed ID: 6147364
    [Abstract] [Full Text] [Related]

  • 29. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R, Tschopp TB, Mittelholzer E, Baumgartner HR.
    J Pharmacol Exp Ther; 1985 Oct 28; 235(1):212-9. PubMed ID: 2995647
    [Abstract] [Full Text] [Related]

  • 30. Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers.
    Valone FH.
    Thromb Res; 1987 Mar 01; 45(5):427-35. PubMed ID: 3590086
    [Abstract] [Full Text] [Related]

  • 31. Imidazoquinoline derivatives: potent inhibitors of platelet cAMP phosphodiesterase which elevate cAMP levels and activate protein kinase in platelets.
    Seiler S, Gillespie E, Arnold AJ, Brassard CL, Meanwell NA, Fleming JS.
    Thromb Res; 1991 Apr 01; 62(1-2):31-42. PubMed ID: 1649498
    [Abstract] [Full Text] [Related]

  • 32. Differential effects of nifedipine, verapamil, and diltiazem on noradrenaline-induced contractions, adrenergic transmitter release, and alpha-adrenoceptor binding in the female rabbit urethra.
    Larsson B, Högestätt ED, Mattiasson A, Andersson KE.
    Naunyn Schmiedebergs Arch Pharmacol; 1984 May 01; 326(1):14-21. PubMed ID: 6147759
    [Abstract] [Full Text] [Related]

  • 33. Effects of some calcium antagonists on aggregation by adrenalin and serotonin and on alpha-adrenoceptor radioligand binding in human platelets.
    Vinge E, Andersson TL, Larsson B.
    Acta Physiol Scand; 1988 Jul 01; 133(3):407-16. PubMed ID: 2906509
    [Abstract] [Full Text] [Related]

  • 34. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
    Liao CH, Tzeng CC, Teng CM.
    Eur J Pharmacol; 1998 May 15; 349(1):107-14. PubMed ID: 9669503
    [Abstract] [Full Text] [Related]

  • 35. Calcium flow-independent actions of calcium channel blockers in toad urinary bladder.
    Levine SD, Levin DN, Schlondorff D.
    Am J Physiol; 1983 Mar 15; 244(3):C243-9. PubMed ID: 6299112
    [Abstract] [Full Text] [Related]

  • 36. Chronotropic, inotropic, and vasodilator actions of diltiazem, nifedipine, and verapamil. A comparative study of physiological responses and membrane receptor activity.
    Millard RW, Grupp G, Grupp IL, DiSalvo J, DePover A, Schwartz A.
    Circ Res; 1983 Feb 15; 52(2 Pt 2):I29-39. PubMed ID: 6831652
    [Abstract] [Full Text] [Related]

  • 37. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
    Simpson AW, Reeves ML, Rink TJ.
    Biochem Pharmacol; 1988 Jun 15; 37(12):2315-20. PubMed ID: 2455518
    [Abstract] [Full Text] [Related]

  • 38. Inhibition of human platelet aggregation by dihydropyrano- and dihydrofuranocoumarins, a new class of cAMP-phosphodiesterase inhibitors.
    Thastrup O, Knudsen JB, Lemmich J, Winther K.
    Biochem Pharmacol; 1985 Jun 15; 34(12):2137-40. PubMed ID: 2988567
    [Abstract] [Full Text] [Related]

  • 39. Antiplatelet activity of semotiadil fumarate.
    Wolfram RM, Kritz H, Oguogho A, Sinzinger H.
    Thromb Res; 2002 May 15; 106(4-5):187-90. PubMed ID: 12297124
    [Abstract] [Full Text] [Related]

  • 40. Dihydropyridine Ca2+ entry blockers selectively inhibit peak I cAMP phosphodiesterase.
    Norman JA, Ansell J, Phillips MA.
    Eur J Pharmacol; 1983 Sep 16; 93(1-2):107-12. PubMed ID: 6313398
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.